🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Twist Bioscience Corporation TWST R2K

Healthcare · Diagnostics & Research · United States
https://www.twistbioscience.com

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

READ MORE ›
$66.87
+128.23% 1Y

Market & Price

Market Cap
$4.16B
Current Price
$66.87
High / Low (52W)
$69.03 / $24.16
Beta
2.23

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
-
Book Value
$7.32
Price to Book
9.13
P/S
10.17
EV/EBITDA
-37.36
Dividend Yield
-

Profitability & Returns

ROCE
-24.75%
ROE
-18.16%
ROA
-12.93%
Profit Margin
-19.85%
Op Margin
-34.92%
EPS (Latest Qtr)
$-0.71
EPS (TTM)
$-1.32

Balance Sheet & Liquidity

Debt/Equity
0.24
Quick Ratio
2.04
Current Ratio
2.70
Debt
$110.84M
Total Assets
$641.86M
Current Assets
$332.97M
Working Capital
$241.56M

Ownership

Promoter Holding
1.30%
Chg in Prom Hold
-0.00%
FII / Inst Holding
123.96%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
$4.10B
Total Revenue (TTM)
$409.48M
EBITDA
$-109.83M
Free Cash Flow
$-58.48M
Operating Cash Flow
$-55.59M
Shares Outstanding
62.27M
Gross Margin
52.07%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
22.76%
Profit 5Y
21.45%
Revenue (YoY)
19.30%
Earnings (YoY)
-

PROS

  • Compounding revenue at 22.8% over 5 years.
  • Profit CAGR of 21.4% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 TWST Twist Bioscience Corporation R2K 66.87 - $4.16B - -24.75% -18.16% 22.76% 21.45%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Dec 2017Mar 2018Jun 2018Dec 2018Mar 2019Jun 2019Dec 2019Mar 2020Jun 2020Dec 2020Mar 2021Jun 2021Dec 2021Mar 2022Jun 2022Dec 2022Mar 2023Jun 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 4.31M6.17M6.54M11.49M13.56M13.60M17.16M19.30M21.21M28.16M31.20M35.02M42.02M48.13M56.11M54.24M60.18M63.74M71.50M75.30M81.46M--92.79M96.06M99.01M103.70M110.72M
Cost of Revenue -----------------------46.77M44.76M48.17M49.73M53.59M
Gross Profit -----------------------46.03M51.30M50.84M53.97M57.12M
Operating Expenses -----------------------87.59M81.42M80.77M87.07M95.78M
Operating Income -16.75M-16.62M-17.49M-22.90M-26.26M-28.12M-55.83M-32.09M-28.20M-32.79M-38.00M-42.12M-55.94M-60.80M-61.16M-44.63M-61.64M-60.78M-46.98M-48.89M-88.92M---41.56M-30.12M-29.93M-33.10M-38.66M
EBITDA ------------------------35.16M-24.05M-23.93M-26.91M-32.24M
Interest Expense ---------------------29.00K24.00K143.00K----
Pretax Income ------------------------39.15M20.58M-26.88M-30.25M-43.98M
Tax Provision -----------------------175.00K191.00K257.00K253.00K43.00K
Net Income -16.94M-16.87M-17.62M-22.64M-25.93M-27.92M-55.64M-31.77M-28.21M-32.90M-37.92M-40.04M-45.56M-60.67M-60.52M-41.82M-59.16M-57.40M-43.01M-45.49M-85.57M---39.33M20.39M-27.14M-30.51M-44.02M
Diluted EPS -----------0.78-0.82-0.91-1.13-1.08-0.74-1.04-1.01-0.75-0.79-1.47---0.660.33-0.45-0.50-0.71
R&D Expense 4.30M4.71M5.27M7.27M8.91M9.01M10.30M10.63M10.44M14.00M15.79M19.84M22.63M31.23M36.84M31.24M27.38M24.53M23.10M24.15M22.47M-21.31M23.92M18.05M-17.13M19.70M

Profit & Loss (Annual)

Figures in USD.

Metric Sep 2017Sep 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Revenue 10.77M25.43M54.38M90.10M-203.56M245.11M312.97M376.57M
Cost of Revenue -----119.33M155.38M179.62M185.57M
Gross Profit -----84.23M89.73M133.35M191.00M
Operating Expenses -----333.26M296.63M309.25M327.26M
Operating Income -58.48M-70.56M-108.85M-140.08M--249.02M-206.90M-175.90M-136.26M
EBITDA ------211.68M-177.59M-144.47M-111.41M
Interest Expense ----367.00K80.00K5.00K29.00K-
Pretax Income ------228.27M-203.47M-208.17M-76.95M
Tax Provision ------10.41M1.15M560.00K719.00K
Net Income -59.31M-71.24M-107.67M-139.93M--217.86M-204.62M-208.73M-77.67M
Diluted EPS ----3.57--4.04-3.60-3.60-1.30
R&D Expense 19.17M20.35M35.68M43.01M69.07M120.31M106.89M90.85M80.28M

Compounded Sales Growth

5 Years:22.76%
1 Year:19.30%

Compounded Profit Growth

5 Years:21.45%
1 Year:-

Stock Price Performance

1 Year:+128.23%
6 Months:+114.95%
3 Months:+42.52%
1 Month:+17.94%

Balance Sheet (Annual)

Figures in USD.

Metric Sep 2016Sep 2017Sep 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Total Assets --115.79M186.99M398.88M-961.38M776.40M614.32M641.86M
Current Assets ------596.48M424.26M346.78M332.97M
Cash & Equivalents -31.23M80.76M46.73M93.67M-378.69M286.47M226.32M183.05M
Inventory ------39.31M32.06M24.08M28.31M
Receivables ------40.29M44.06M34.90M57.02M
Total Liabilities --26.73M34.91M62.62M-171.99M152.97M141.63M168.90M
Current Liabilities --18.54M30.35M36.03M-90.66M73.32M71.01M91.41M
Long Term Debt --7.22M4.40M1.40M-----
Total Debt ------94.91M94.07M85.03M75.57M
Total Equity -76.61M-133.36M-201.42M152.08M336.26M-789.38M623.43M472.69M472.96M
Shares Outstanding ------56.52M57.56M58.88M60.63M

Cash Flows (Annual)

Figures in USD.

Metric Sep 2017Sep 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Operating Cash Flow -51.30M-66.16M-87.94M-142.25M--124.39M-142.47M-64.09M-47.63M
Investing Cash Flow -9.99M27.31M-104.81M-114.65M--232.93M50.61M-3.07M-24.76M
Financing Cash Flow 63.80M88.82M158.58M303.73M-270.53M911.00K6.89M28.54M
Capital Expenditure -6.59M-3.69M-14.76M-9.87M--101.86M-27.78M-5.08M-28.00M
Free Cash Flow -57.90M-69.85M-102.69M-152.12M--226.24M-170.25M-69.17M-75.63M
Net Change in Cash ------86.78M-90.95M-60.27M-43.85M

Ratios (Annual)

Figures in %.

Metric Sep 2017Sep 2018Sep 2019Sep 2020Sep 2021Sep 2022Sep 2023Sep 2024Sep 2025
Gross Margin % -----41.4%36.6%42.6%50.7%
Operating Margin % -543.2%-277.5%-200.1%-155.5%--122.3%-84.4%-56.2%-36.2%
Net Margin % -550.8%-280.2%-198.0%-155.3%--107.0%-83.5%-66.7%-20.6%
ROE % 44.5%35.4%-70.8%-41.6%--27.6%-32.8%-44.2%-16.4%
ROCE % --72.6%-69.5%-38.6%--28.6%-29.4%-32.4%-24.8%

Shareholding Pattern

Insiders
1.30%
Institutions
123.96%
Public Float
125.59%

Top Institutional Holders

#Holder% HeldSharesValue
1 Artisan Partners Limited Partnership 10.23% 6.37M $425.81M
2 ARK Investment Management, LLC 10.19% 6.34M $424.14M
3 Blackrock Inc. 8.92% 5.55M $371.42M
4 Edgepoint Investment Group Inc. 8.64% 5.38M $359.93M
5 William Blair Investment Management, LLC 8.46% 5.27M $352.39M
6 State Street Corporation 5.89% 3.67M $245.46M
7 Vanguard Portfolio Management LLC 4.25% 2.65M $177.15M
8 Vanguard Capital Management LLC 4.24% 2.64M $176.47M
9 Invesco Ltd. 3.49% 2.17M $145.23M
10 FMR, LLC 3.04% 1.89M $126.38M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TWST

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks